Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8931 plus Anastrozole in Advanced Breast Cancer
NCT01151215Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial of sapitinib in breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression Free Survival at 12 weeks. Started Jun 2010; status: terminated.
02
Drugs
sapitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01151215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01151215.